FDA Approves HEPARIN SODIUM — Hospira, Inc.

Hospira, Inc. received approval from the FDA for its generic Heparin Sodium injection, a strategic move likely to deepen the company's share in the acute care market but potentially highlighting risks associated with its reliance on low-margin, high-volume generics. This approval is set to increase competitive pricing pressure within the injectable space, while also raising questions regarding Hospira's overall profitability and diversity of portfolio due to the pending fallout from its ValvaPro heart valve recall.